Stem Cell Network Welcomes New Appointments to its Board of Directors

November 23, 2020 (Ottawa) – The Stem Cell Network (SCN) is pleased to announce the appointments of Deborah Gordon-El-Bihbety and Gordon C. McCauley to its Board of Directors, effective November 20, 2020. SCN’s Board is comprised of Canadian leaders representing research, industry, healthcare, and the not-for-profit sectors.

“Ms. Gordon-El-Bihbety and Mr. McCauley bring to our Board an incredible depth of knowledge and range of experience at the national level. Both individuals have built their impressive careers translating research – to government and to industry – which aligns perfectly with SCN’s goal to translate science from the lab to clinical applications, commercial products, and public policy for the benefit of Canadians,” said Dr. Michael Rudnicki, O.C., Scientific Director & CEO of SCN.

As President and CEO of Research Canada for the past 17 years, Deborah Gordon-El-Bihbety brings considerable executive-level experience to Research Canada in the areas of public policy, health advocacy, government relations, association management, project management and media. Before joining the organization in 2003, Ms. Gordon-El-Bihbety was the Associate Chief Executive Officer at the Canadian Public Health Association.

“SCN has been a longstanding and valued partner of Research Canada,” remarked Ms. Gordon-El-Bihbety, “I am thrilled to be able to join forces as a member of the Stem Cell Network Board of Directors to continue to advance our shared goals in support of Canadian health research and policy for the benefit of all Canadians.”

An accomplished life science investor and executive, Gordon McCauley was appointed President and CEO of adMare BioInnovations in 2017. Prior to joining adMare, Mr. McCauley served as President and CEO of several organizations, including Viable Healthworks Corporation, Allon Therapeutics Inc., and was Co-Founder and Partner of NDI Capital, an institutionally backed life-science investment fund.

“adMare BioInnovations is focused on being a catalyst for the Canadian life science industry, providing  specialized expertise, infrastructure, and capital to ensure Canadian biotech companies lead the world,” explained Mr. McCauley. “The Stem Cell Network is a trusted leader in the stem cell and regenerative medicine sector, and I am honoured to have the opportunity to work with the Board and Management on charting a future course that will see Canadian advances in regenerative medicine translated and commercialized for the benefit of all.”

Stem Cell Network would also like to extend heartfelt thanks to Dr. Fabio Rossi, Professor at the University of British Columbia, and Canada Research Chair in Regenerative Medicine, who is stepping down from the Board after more than a decade of service.

“Since joining the Board in December 2008, Dr. Rossi has been integral to the success of our Network,” explained Dr. Rudnicki. “His vision and leadership helped to guide us through a few challenges and many unparalleled successes. We thank him for his service to the Network and look forward to continuing our collaboration in new and exciting ways.”

Full list of SCN’s Board members and Research Management Committee members.

-30-

About the Stem Cell Network
The Stem Cell Network (SCN) is a national non-profit that supports stem cell and regenerative medicine research, training the next generation of highly qualified personnel, and delivering outreach activities across Canada. SCN’s goal is to advance science from the lab to the clinic for the benefit of Canadians. SCN has been supported by the Government of Canada since inception in 2001. This strategic funding, valued at $118M, has benefitted approximately 196 world-class research groups and over 3,300 trainees and has catalyzed 24 clinical trials.
Tomorrow’s health is here.  stemcellnetwork.ca